- Company
- Ilaris can be prescribed at general hospitals in KOR
- by Eo, Yun-Ho Oct 8, 2024 05:49am
- Ilaris, which was listed for reimbursement 9 years after receiving marketing authorization in Korea, can now be prescribed at general hospitals in Korea. According to industry sources, Novartis Korea's hereditary recurrent fever syndrome drug Ilaris (canakinumab) has passed the drug committees (DCs) of Seoul National University Hospital,
- Company
- Eisai Korea signs Alzheimer's MOU with the Korean Dementia
- by Whang, byung-woo Oct 8, 2024 05:49am
- Eisai Korea announced on October 7th that it has signed a memorandum of understanding (MOU) with the Korean Dementia Association to utilize and manage 'JOY-ALZ,' a registry program for long-term follow-up survey platform of Alzheimer's disease prognosis. The MOU aims to advance Alzheimer's disease treatment and to establish safe Alzheime
- Company
- Galderma Korea appoints Jai Hyuk Lee as new GM
- by Whang, byung-woo Oct 8, 2024 05:48am
- Galderma Korea announced on the 7th that it has appointed Jake (Jai Hyuck) Lee, former head of the Aesthetics Business Unit, as its new General Manager, effective as of October 1. The new GM is a seasoned sales and marketing expert with more than 25 years of experience in the global pharmaceutical and aesthetics industries. Lee will succe
- Company
- Yuhan·Dongwha as potential distributor for Bayer's OTC drug
- by Nho, Byung Chul Oct 7, 2024 05:48am
- Bayer seeks a new distributor·seller for its leading over-the-counter (OTC) medications, including 'Canesten·Bepanthen.' According to industry sources, Bayer is searching for a new distributor to distribute its OTC medications, Canesten and Bepanthen, ahead of the termination of its OTC co-promotion agreement with Il Dong Pharmaceutic
- Company
- Darzalex seeks reimbursement extensions again in KOR
- by Whang, byung-woo Oct 7, 2024 05:48am
- With Janssen Korea reapplying to extend the reimbursement of its Darzalex (daratumumab), which it first failed at the Drug Reimbursement Evaluation Committee’s stage, whether the company will succeed in making progress in its discussions this time is gaining attention. According to industry sources on the 4th, the Health Insurance Revie
- Company
- No new news on reimb extension of Lorviqua for 4mths
- by Eo, Yun-Ho Oct 7, 2024 05:48am
- No progress has been made on the discussions on the ALK inhibitor anticancer drug ‘Lorviqua,’ which the company had reapplied for first-line reimbursement benefits immediately upon failing to successfully conclude its first drug pricing negotiations. According to industry sources, the health authorities have not decided at what stage th
- Company
- Camzyos’s reimbursement decision imminent
- by Moon, sung-ho Oct 4, 2024 04:38am
- Obstructive hypertrophic cardiomyopathy (oHCM), has been regarded as a difficult-to-treat area due to the lack of a cure. However, with the recent introduction of new drugs and reimbursement granted for its diagnostic test, expectations are rising for a paradigm shift in oHCM treatment &8211; the key to which will be whether or not the newly
- Company
- Expectations rise for the reimbursement of Phesgo in Korea
- by Whang, byung-woo Oct 4, 2024 04:38am
- On the 30th, Roche Korea announced that the socio-economic benefits of Phesgo (pertuzumab/trastuzumab) for early-stage and metastatic HER2-positive breast cancer were highlighted at the 2024 Korean Society of Medical Oncology (KSMO) Congress. The 2024 Korean Society of Medical Oncology (KSMO) Fall Meeting, which was held at COEX, brings t
- Company
- Biologics seek to expand indications…is approved for COPD
- by Son, Hyung Min Oct 4, 2024 04:38am
- Biological agents are expanding their reach beyond inflammatory diseases such as atopic dermatitis, oesophagitis, and asthma to lung disease. Recently, Sanofi and Regeneron's biologic Dupixent was approved by the US Food and Drug Administration (FDA) for the treatment of chronic obstructive pulmonary disease (COPD). Other biologics, such as GSK'
- Company
- "Importance of fungal infections TX amid COVID-19 spike"
- by Son, Hyung Min Oct 4, 2024 04:38am
- "Fungal infections usually occur in immunocompromised patients and have a high fatality rate. Because fungal infections can be fatal to patients, especially during the resurgence of infectious diseases, such as COVID-19, it is of paramount importance to secure various treatment options." During a recent meeting with Daily Pharm, Sung-Yeon
